Angiotensin I (Plasma Renin activity) ELISA
- Regulatory Status
- RUO
- Kit size
- 192 (96)
- Method
- ELISA
- Incubation time
- 1 x 1h, 1 x 30min, 1 x 15min
- Standard range
- 0.2 - 60 ng/mL
- Specimen / Volumes
- 500µL EDTA Pasma
- Substrate / isotope
- TMB 450 nm
For the quantitative determination of Plasma Renin Activity (PRA) in human plasma by an enzyme
immunoassay. For research use only. Not for use in diagnostic procedures.
For concrete data please consult the Instruction for Use in the download box on the top right side.
[1] Spence JD. (1999) Physiologic tailoring of therapy for resistant hypertension: 20 years' experience with stimulated renin profiling. Am J Hypertension. 12(11 Pt 1):1077-83.
[2] Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, III, Riehle JF, et al. (2009) Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 22(7):792-801.
[3] Tan ACITL, Kloppenborg PWC, Benraad TJ. (1989) Influence of Age, Posture and Intra-Individual Variation on Plasma Levels of Atrial Natriuretic Peptide. Annals of Clinical Biochemistry. 26(6):481-486.
[4] Tiu, S. C., Choi, C. H., Shek, C. C., Ng, Y. W., Chan, F. K., Ng, C. M., & Kong, A. P. (2005). The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. The Journal of clinical endocrinology and metabolism, 90(1), 72–78..
[5] Sealey JE, Gerten-Banes J, Laragh JH (1972), The renin system: Variations in man measured by radioimmunoassay or bioassay Kidney International 1:240-253.
[6] Sealey, J. E., Gordon, R. D., & Mantero, F. (2005). Plasma renin and aldosterone measurements in low renin hypertensive states. Trends in endocrinology and metabolism. TEM, 16(3), 86–91.
[7] J. Brossaud and J.B. Corcuff, (2009) Pre-analytical and Analytical Considerations for the Determination of Plasma Renin Activity, Clinica Chimica Acta 410:90–92.
[8] F. K. Suessenbach, B. B. Burckhardt. Levels of angiotensin peptides in healthy and cardiovascular/ renal - diseased paediatric population—an investigative review. Heart Failure Reviews (2019) 24:709–723
[9] https://doi.org/10.1007/s10741-019-09797-y
[10] Guoqing Yao, Wenjing Li, Wenzhao Liu, et al. (2021) The Level and Significance of Circulating Angiotensin-III in Patients with Coronary Atherosclerosis. Hindawi Journal of the Renin-Angiotensin-Aldosterone System. 1704762,
[11] Valle Martins AL, da Silva FA, Bolais-Ramos L, et al. (2021) Increased circulating levels of angiotensin-(1–7) in severely ill COVID-19 patients. ERJ Open Res 7: 00114-2021 [DOI: 10.1183/23120541.00114-2021].
[12] Clare A. McKinney, Caroline FATTAH, Christopher M. Loughrey et al. (2014) Angiotensin-(1–7) and angiotensin-(1–9): function in cardiac and vascular remodelling. Clinical Science. 126, 815–827 (Printed in Great Britain) doi: 10.1042/CS20130436
[13] Stirati G, de Martino A, Mene P, et al. (1983) Plasma renin activity: effect of temperature during blood processing. J Clin Chem Clin Biochem 529-31
[14] Ruth Lapworth, Sally E Green and Frances Short. (1990) In vitro stability of assayed renin activity in plasma and whole blood. Ann Clin Biochem 27: 78-79
[15] Zoltan Locsei, Karoly Racz, Attila Patocs et al. (2009). Influence of sampling and storage conditions on plasma renin activity and plasma renin concentration. Clinica Chimica Acta 402 203–205
[16] Morganti, A; Lonati, C; Turolo, L (2010) Brief Cryoactivation Markedly Affects Plasma Renin Activity and Direct Renin Measurement in Low Renin Samples: PP.24.473, Journal of Hypertension: 28 p e388 doi: 10.1097/01.hjh.0000379399.50039.3c.
[17] Sealey JE. (1991) Plasma renin activity and plasma prorenin assays. Clin Chem. 37(10 Pt 2):1811-9. PMID: 1914195.
[18] Campbell, D. J., Nussberger, J., Stowasser, M., Danser, A. H., Morganti, A., Frandsen, E., & Ménard, J. (2009). Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clinical chemistry, 55(5), 867–877.
[19] Brossaud J, Corcuff JB. Pre-Analytical and Analytical Considerations for the Determination of Plasma Renin Activity. Clin Chim Acta. 2009; 410(1–2):90–2.
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
At Tecan, we are driven to improve people’s lives and health.